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Pediatric acute-onset neuropsychiatric 
syndrome 
A B S T R A C T   
Objective: Pediatric acute-onset neuropsychiatric syndrome (PANS) is a complex neuropsychiatric syndrome 
characterized by an abrupt onset of obsessive-compulsive symptoms and/or severe eating restrictions, along with 
at least two concomitant debilitating cognitive, behavioral, or neurological symptoms. A wide range of phar-
macological interventions along with behavioral and environmental modifications, and psychotherapies have 
been adopted to treat symptoms and underlying etiologies. Our goal was to develop a data-driven approach to 
identify treatment patterns in this cohort. 
Materials and methods: In this cohort study, we extracted medical prescription histories from electronic health 
records. We developed a modified dynamic programming approach to perform global alignment of those 
medication histories. Our approach is unique since it considers time gaps in prescription patterns as part of the 
similarity strategy. 
Results: This study included 43 consecutive new-onset pre-pubertal patients who had at least 3 clinic visits. Our 
algorithm identified six clusters with distinct medication usage history which may represent clinician’s practice 
of treating PANS of different severities and etiologies i.e., two most severe groups requiring high dose intrave-
nous steroids; two arthritic or inflammatory groups requiring prolonged nonsteroidal anti-inflammatory drug 
(NSAID); and two mild relapsing/remitting group treated with a short course of NSAID. The psychometric scores 
as outcomes in each cluster generally improved within the first two years. 
Discussion and conclusion: Our algorithm shows potential to improve our knowledge of treatment patterns in the 
PANS cohort, while helping clinicians understand how patients respond to a combination of drugs.   
1. Introduction 
In cohorts of patients with multiple medication usage 
–polypharmacy– it is important to understand if there are groups of 
patients that share similar patterns of usage and what are the differences 
between these groups of patients. Polypharmacy is common in older 
patients with multimorbidity [1]; and it is associated with adverse 
outcomes including mortality and adverse drug reactions [2], increased 
length of stay in hospital and readmission to hospital soon after 
discharge [3]. Polypharmacy can also occur in children and adolescent 
patients with psychiatric diseases [4], and other non-elder adults with 
complex chronic syndromes such as lupus [5], human immunodefi-
ciency virus (HIV) infection [6], ischemic and respiratory diseases [7], 
or cancer [8]. These diseases are often multifactorial, with physicians 
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treating related, but separate, symptoms and pathologies. One of these 
syndromes is the pediatric acute-onset neuropsychiatric syndrome 
(PANS). 
The PANS clinical presentation [9] is characterized by abrupt-onset 
of obsessive-compulsive disorder and/or food restriction, along with at 
least two other severe neuropsychiatric symptoms from the following 
categories: anxiety; mood lability or depression; irritability, opposi-
tionality, or rage; behavioral regression; deterioration in school per-
formance/cognitive difficulties; sensory or motor abnormalities; and 
somatic symptoms like sleep disturbances or enuresis. Patients typically 
experience a relapsing-remitting course in which disease flares are 
interspersed with remissions [10]. In some cases, the disease course is 
chronic, when the patient’s neuropsychiatric status does not return to 
baseline. 
Current evidence suggests that PANS has an inflammatory or auto-
immune etiology that is associated with an infection [11–16]. A recent 
MRI study in children with PANS showed an increased median diffu-
sivity in multiple brain structures including basal ganglia, thalamus and 
amygdala compared to controls, suggesting neuroinflammation in these 
regions. Multidisciplinary clinics are well-positioned to care for patients 
with PANS [17]. Although treatment protocols are lacking, interim 
guidelines suggest using antibiotics to treat or prevent infections, 
immunomodulatory therapies to manage inflammation, and psychiatric 
medications supplemented with cognitive behavioral therapy to treat 
PANS [18]. The heterogeneity and complexity of PANS presentation, 
clinical course, treatment, insurance status, and irregular follow-up 
make it difficult to compare treatment courses across patients and 
patient-groups. The difficulties in documenting an association between 
streptococcal infection and symptom onset/exacerbations makes it 
challenging to understand when to use antibiotics such as penicillin [9], 
A novel method to cluster patients given their temporal medication 
prescriptions, is needed to identify potential disease subgroups. 
In precision medicine, patient similarity is an emerging concept that 
aims to help discover groups of patients (clusters) that share similar 
characteristics estimating a numerical distance between components of 
patient data [19]; and ultimately, to use those clusters in predictive 
modeling tasks [20]. The data features commonly used include de-
mographics and population characteristics [21], genetics [22], pre-
scriptions and lab tests [23,24], medical billing codes [25], and even 
clinical narratives processed with natural language tools [26]. Mean-
while, commonly used algorithms for this task employ distance-based 
functions that consider geometrical space (e.g. Euclidean, Manhattan, 
etc.) [23,27]; machine learning models that employ representations of 
patients in the multivariate space (e.g. decision trees [28] or random 
forests [29]); and the use of ontologies to find hierarchically related 
concepts (e.g. patients with closely related diagnosis [30]). However, 
the temporal dimension of the patient journeys is often not addressed by 
these algorithms, which requires a broader exploration. 
Previous work using temporal information encoded clinical events 
into streams of information, enabling the use of sequence alignment 
algorithms in bioinformatics pipelines. Recently, Ledieu et al. [31] used 
a modified version of the Smith-Waterman sequence local alignment 
algorithm for pharmacovigilance in electronic medical records, detect-
ing inadequate treatment decisions in patient sequences. Meanwhile, 
Lee & Das [32] developed a local sequence alignment strategy to find 
HIV patients with similar treatment histories, leveraging a simple 
ontology to improve local alignment of antiretroviral regimens. The use 
of the ontology certainly adds value to the algorithm, but it is also a 
limitation if the ontology is not well defined or unknown, for example in 
the case of the PANS patients. 
In this study, we developed a modified version of the global align-
ment Needleman-Wunsch algorithm to the medication prescription 
patterns of a PANS cohort from Stanford University to elucidate groups 
of patients with similar treatment patterns. Our medication alignment 
algorithm MedAl retrospectively finds patients with similar prescription 
patterns, and groups them into clusters to associate their overall 
impairment scores. Our goal was to provide a data-driven approach to 
identify treatment patterns in the PANS cohort. 
2. Materials and methods 
This is a retrospective cohort study, using patient/parent question-
naires and ledgers collected routinely as part of clinical care, as well as 
electronic medical records (EMR) data. The objective was to understand 
patterns of medication usage in patients. Our study involved extracting 
data from electronic health records, using MedAl to create a patient 
similarity metric, grouping patients into clusters, visualizing them, 
evaluating the cluster assignment, and validating the clusters with 
clinical outcomes in the PANS cohort. The study outline is shown in 
Fig. 1, where our algorithm MedAl allows for downstream clustering by 
defining a distance between the study subjects. 
Clinical setting and population 
The pilot study took place at the Stanford PANS clinic located in 
California, United States of America, which is a multidisciplinary clinic 
staffed by practitioners of various disciplines (psychiatry, primary care, 
rheumatology, immunology), as well as a social work psychotherapist 
and an education specialist. 
The data used in this study were generated during clinical care and 
includes prospectively collected impairment scores (global impairment 
and caregiver burden inventory), but we also retrospectively collected 
medication use data abstracted from the clinical charts. Data were 
collected on those patients seen between the clinic inception on 
September 3rd, 2012, and the patient cohort identification date for this 
study, January 31st, 2018. In this period there were 305 patients seen in 
clinic, out of which we excluded: those whose parents refused consent 
Fig. 1. Study outline.  
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for the study (N = 4), those patients who did not meet the strict PANS 
criteria [9] (N = 97), had fewer than three visits to the PANS clinic (N =
36), were older than 12 years at clinic entry (N = 60) and presented to 
the clinic more than 4 months after onset of psychiatric symptoms (N =
65). The final cohort includes 43 pre-pubertal new-onset patients, as 
shown in Supplementary Material 1. One patient was dropped from the 
primary analysis because the only medication was taken after the first 
two years at the clinic. 
We only included patients with established care with the clinic (at 
least three visits) because the first few visits aim to understand the 
history and disease course, to examine patients and to counsel parents 
about different treatment options. We used a cut-off age of 12 years to 
include only pre-pubertal children, as hormones might play a role in 
psychiatric symptoms and behaviors [33]. We restricted patients to 
those with such a short time difference between PANS onset and first 
PANS clinic appointment because we wanted to analyze patients with 
new-onset PANS, for whom we had more complete information close to 
the beginning of their PANS illness. 
Data sources 
We collected data on medical treatment from the electronic medical 
record using a keyword search method [34], and we made a final update 
of medication history in mid-October 2018. For this patient group, a 
limited number of medications are offered and were decided upon a 
priori by the clinical team. We excluded short courses (less than 21 days) 
of antibiotics for acute infections, NSAID taken as needed by patients, 
and psychiatric medications as the aim of this analysis was to study the 
similarity of using medical (non-psychiatric/non-psychological) thera-
pies in this group of patients. Our medication keyword search method is 
outlined in Table 1. 
For medications taken daily, we determined the start and stop dates. 
For medications with long acting effects (i.e. Rituximab, IV corticoste-
roids) we determined the start date only. In some cases, determining 
start and stop dates is challenging. For example, a patient/parent may 
have decided to discontinue a medication between two clinic visits but 
failed to recall the exact stop date. In these cases, we estimated the stop 
date using one of two methods: a) if the provider estimated a unit of time 
during which patient stopped taking the medication, we used the 
midpoint of that unit of time (e.g. “patient stopped NSAIDs March 2017” 
would be coded as March 15, 2017; early March will be coded as March 
1; late March will be coded as March 30; two weeks ago will be 14 days 
before the encounter date); b) if no estimate was given, we used the 
clinic visit date on which the provider reported the patient stopped 
taking the medication as the stop date. All stop dates for active medi-
cations were set at the last visit dates. If a patient suspended the drug for 
less than a week, we would consider it to be a continuous use; otherwise, 
we would state two separate periods. 
Patient outcomes 
In the PANS cohort, like in many other psychiatric syndromes, 
evaluating outcomes is a complex task which requires the use of scales 
and assessment scores that are subjective in nature. The Stanford PANS 
clinic utilizes two parent rated impairment scales that have been vali-
dated in this patient population: 
Global Impairment Scale [35]. A scale ranging from 0 to 100, where 
the highest value indicates severe challenges for the patient to 
interact with others and carry on their daily activities, and the lowest 
value indicates a child without impairment. 
Caregiver Burden Inventory [36]. A scale ranging from 0 to 96, where 
the highest value indicates the greatest caregiver burden. A score 
greater than 36 indicates respite care [37]. 
The Stanford PANS clinic collects electronic patient questionnaires 
that caregivers and patients fill out before each clinic visit. The ques-
tionnaire queries symptom-specific scales corresponding to the severity 
of the patient symptoms. The outcome data (Global Impairment and 
Caregiver Burden) may be skewed by the fact that the frequency of 
follow-up clinic visits and corresponding completed questionnaires 
trends with the severity of the psychiatric symptoms (i.e. when patients 
Table 1 
Medication list and keywords (underlined) used in the EMR search-box.  
Class Generic name Brand 
name 
Common use Freq* Admin. 
Antibiotic (Penicillin) Penicillin G Various Streptococcal infection and prophylaxis against strep Once every 
3–4 weeks 
IM  
Penicillin V Various Idem Daily Oral  
Amoxicillin Amoxil Commonly used to treat otitis media, sinusitis, and streptococcal 
infections 
Daily Oral  
Amoxicillin + Clavulanate 
potassium 
Augmentin idem Daily Oral 
Antibiotic (Cephalosporin) Cefalexin Keflex Gram-positive infections Daily Oral  
Cefadroxil Duricef Idem Daily Oral 
Antibiotic with Anti- 
inflammatory Effect 
(Macrolide) 
Azithromycin Zithromax Streptococcal and Mycoplasma infections, syphilis, respiratory 















Anti-inflammatory Daily Oral 
Corticosteroids (oral) Prednisone Prednisone Anti-inflammatory Daily Oral  
Dexamethasone Decadron Anti-inflammatory Daily Oral 
Corticosteroids (IV) Methylprednisolone Solumedrol Anti-inflammatory Short course 




Various Inflammatory diseases and immunodeficiencies Short course 
over 1–3 days 
IV 
Disease-modifying anti- 
rheumatic drug (DMARD) 
Rituximab Rituxan Autoimmune disease One round 
over a day 
IV  
Methotrexate Various Anti-rheumatic Daily Oral or 
SC  
Mycophenolate mofetil Cellcept Anti-rheumatic Daily Oral 
After keywords were highlighted, clinical records were reviewed in detail to ensure that the patient was taking the medication as listed. Abbreviations: Freq: Frequency 
of administration; Admin: Route of administration; IM: intramuscular; IV: intravenous; SC: subcutaneous. 
*Daily dose can be divided into several doses. 
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are highly symptomatic, they come to the clinic weekly for psychiatric 
medication titration and therapy, but when the child improves/resolves 
their psychiatric symptoms, it is difficult to get the family to return to 
clinic). An example of the medication journey and outcome for a 
selected PANS patient in this cohort is shown in Fig. 2. 
A modified sequence alignment algorithm 
In this manuscript, we propose medication alignment for patient 
similarity (MedAl) algorithm, that adapts a protein sequence alignment 
paradigm [38,39] to medication usage history. The alignment edit dis-
tance is used to estimate medication usage similarity, in order to 
construct a clustering strategy. The algorithm is as follows: a) encode the 
medication history in a sequence representation; b) perform alignment 
of pairs of medication sequences; and c) compute a weighted patient 
pairwise edit distance. 
Encode the medication history. Medication usage was encoded into a 
binary vector representing daily intake. We considered missing values to 
be not missing at random (NMAR), and therefore assigned an explicit 
missing value (represented by the character ‘∅’). For example, consider 
a patient taking two 3-day rounds of a corticosteroid burst (represented 
by the character ‘C’), followed by two resting days. The encoded version 
for this would be a “CCC∅∅CCC”. 
Sequence alignment. We used a dynamic programming approach to 
align the medication history encoded vectors. There are two steps: (1) 
matrix fill, and (2) traceback. First, we create a data matrix between two 
patient’s histories, and initialize it with zeros in the first column and 
row. The remaining elements of the matrix are filled from left to right 
and top to bottom. For each cell the substitution is evaluated using the 
pattern table shown in Fig. 3 (Panel A). By the end of this step the matrix 
contains all the alignments between the two sequences. The second step 
finds the best alignment by tracing back the path from the bottom right 
corner (end of two patient records) to the top left corner (start of patient 
records) based on the alignment that leads to the score. For a step by step 
annotated example, please refer to Supplementary Material 2. 
It is important to clarify that MedAl is different from other sequence 
alignment algorithms because of the use of its pattern table, corre-
sponding to four medication usage patterns: start of medication, 
continuing medication, end of medication, and continuing gap. For any 
pair of patients there are 16 possible combinations for how the medi-
cation is being administered to both patients, and four penalty calcu-
lations, represented under each tile of Fig. 3 (Panel A): (1) if both 
patients have the same medication usage pattern, then the minimum 
neighboring value is assigned; (2) if one of the patients has switching 
pattern (e.g. the first patient starting medication, and second patient 
continuing medication), then the maximum neighboring value is 
assigned; (3) if both patients have complete opposing patterns (e.g. first 
patient is starting medication while the second patient is ending medi-
cation), then the maximum neighboring value plus one is assigned; and 
(4) lastly, if one of the patients has a pattern involving missing values (e. 
g. first patient is starting medication, while the second patient is not 
taking anything), then the minimum neighboring value plus one is 
assigned. 
Weighted edit distance. The edit distance is a metric of the minimum 
number of operations needed to align two sequences. Traditionally in 
genome sequences, these operations could be insertion of a gap, deletion 
of a position, or substitution for an equivalent letter. However, for 
medication alignment, we only allow insertions, since we do not want to 
delete medication histories, and a substitution for an equivalent letter is 
difficult to assess. In Fig. 3, the minimum distance, for a toy example, is 
shown as the green path. 
Cluster assignment and evaluation 
Assigning patient similarity can be important for diagnostic and 
treatment purposes particularly in hard to diagnose or complex diseases. 
An experienced physician can often provide a measure of this similarity, 
but an automatic score is needed for large databases to evaluate the 
physician prior knowledge (e.g. the cost associated for stopping a drug 
or switching to a new drug can be determined by the physician). If the 
cost is properly assigned, various clustering algorithms should provide 
similar answers. For illustration purposes, we used two well-known 
clustering algorithms: hierarchical clustering and k-means. 
Hierarchical clustering (hclust). This is a popular technique that cre-
ates clusters with an ordering (hierarchy). We selected an 
Fig. 2. Medication journey for a selected PANS patient in the cohort.  
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agglomerative (bottom-up) algorithm with complete linkage. This 
method starts by assigning each sample to its own cluster. Then, to 
join the two most similar patients into a larger cluster, we used the 
MedAl distance. The algorithm continues to recursively aggregate 
clusters until all samples have been added to a single cluster. 
K-means. This clustering method is also a popular clustering method 
which has been previously used in psychiatric disorders [40]. This 
technique aims to partition observations of patients into k clusters in 
which each observation belongs to the cluster with the nearest mean. 
The metric to estimate distance is typically a geometrical distance (e. 
g. Euclidean distance). This metric was not feasible with the medi-
cation history data, therefore MedAl was used. 
We used three metrics to compute external criterions that evaluates 
how well the clustering matches the gold standard classes (normalized 
mutual information (NMI), cluster purity, and cluster entropy). For the 
PANS cohort, the ground truth of cluster assignment is unknown, and 
therefore these metrics only serve to provide confidence on the equiv-
alence of clustering assignment between two methods (hclust and k- 
means). All three methods range from 0, being the worst evaluation, to 
1, being the best evaluation. 
Four quantitative methods were used to estimate the optimal number 
of clusters (k) in the PANS cohort: (a) elbow method, which measures 
the compactness of clusters by summing the within-cluster sum of 
squares; (b) Silhouette method [41], which measures the cohesion of 
clusters, through averaging the distance between each element and the 
rest of the elements in that cluster, and comparing to the average dis-
tance of neighboring clusters; (c) Gap statistic [42], which estimates the 
statistical comparison between the total intra-cluster variation and the 
null hypothesis without cluster assignment; and (d) Clest method [43], 
which is a variation on the gap statistic, selecting the number of clusters 
within a range from the maximum global standard error. 
Evaluation and validation of the assigned clusters was done by 
comparing the aggregated outcomes in two questionnaires the Global 
Impairment score and Caregiver Burden Inventory, where we conducted 
an analysis of variance (ANOVA) accounting for longitudinal sampling 
from each individual. Slopes were fit stratified by cluster using a linear 
mixed-effects model to determine trends within clusters for both scores. 
The null hypothesis was that there is no difference between groups, 
therefore having a p-value smaller than 0.05 would reject this hypoth-




Patient characteristics in this study were evenly distributed by sex, 
and heavily skewed by self-reported race and ethnicity (mostly non- 
Hispanic white) in patients. The age at first neuropsychiatric deterio-
ration occurred on average between 7 and 8 years old, with a rapid 
intake by the PANS clinic (patients seen >4 months after psychiatric 
symptom onset were excluded). Table 2 shows a detailed description of 
the clinical characteristics of this cohort. 
Number of clusters 
A graphical inspection of the methods in Fig. 4 shows disagreement 
between them. The elbow method does not clearly show an elbow, 
suggesting that any number of clusters would show some effect. In the 
Silhouette method, the maximum value was at k = 9 (the highest rated), 
however, there are two good candidates at k = 2 and k = 4. The gap 
statistic method shows the best value at k = 2. The Clest method suggests 
a number of clusters of k = 6. On the other hand, when comparing 
cluster purity, NMI and Entropy, these metrics seem to converge around 
k = 6. 
Cluster assignment 
A critical point in the selection of a cluster assignment is to select an 
appropriate number of clusters. From the metric evaluation shown in 
Fig. 4, there were some good candidates (Gap: k = 2; Clest: k = 6; 
Silhouette k = 9). From Panel E in Fig. 4, we also observed that k = 2 and 
k = 6 had the most similar cluster assignments (lowest entropy, and 
highest NMI and Purity). However, since there was no clear selection of 
the best number of clusters, we used a heatmap with the MedAl score, 
showing how the different patients would cluster together using 
Fig. 3. Dynamic programming approach to medication alignment. (A) Matrix fill step; (B) Traceback step. The path starts from the bottom-right cell and ends at the 
top-left cell of the matrix. Only two insertions were needed to align the sequences. The purple path is an alternative sub-optimal alignment that requires three 
insertions, but this distance is not selected. 
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dendrograms, as shown in Fig. 5, panel A. The heatmap visually grouped 
patients with similar medication journeys (blue isles). We tried out all 
candidates from Fig. 4 (k = 2,6,9), finally choosing k = 6 as the most 
appropriate. For the remainder of the analysis we used k = 6, given that 
it was the number of clusters that most clearly differentiated between 
the groups. 
Cluster characteristics 
We also assessed the qualitative value of the clustering assignment, 
based on the patient similarity metric calculated using MedAl. The 
medication usage by cluster and medication class is shown in Fig. 6. The 
patients were censored at two years of follow-up, and the index date 
used to align all medication histories is the first visit to the PANS clinic. 
Each medication class varies from none of the patients taking that drug 
to all of the patients taking the drug. Clusters 4 and 6, composed by 
patients with the most severe groups requiring high dose IV steroids; 
Clusters 1 and 2, composed by patients requiring prolonged NSAID 
which are used frequently by arthritic or inflammatory diseases; Cluster 
2 was also a group of patients with likely underlying Streptococcal in-
fections treated with penicillin; Clusters 3 and 5, composed by patients 
taking a short course of NSAID for their relapsing/remitting courses of 
PANS illness. The psychometric scores as outcomes in each cluster 
generally improved within the first two years except the group of pa-
tients using prolonged NSAID and likely suffering from arthritic or in-
flammatory diseases that ultimately required more aggressive 
immunomodulation. 
Upon performing an analysis of variance (ANOVA), we found in 
Table 3 that there is significant heterogeneity in trend of scores over 
time within an individual and between clusters for both Global 
Impairment (PANOVA = 0.005) and Caregiver Burden (PANOVA = 0.0004). 
We note that all clusters, with the exception of cluster 2, demonstrate on 
average a decreased Caregiver Burden Inventory and decreased Global 
Impairment Scale over time. This is a sign of general improvement on 
the patient’s condition. 
4. Discussion 
Here we present a method to align patient history to identify distinct 
clusters of medication usage, and we apply the method to a PANS cohort. 
Our approach relies on constructing a symmetric matrix of the pairwise 
distances between patients. The dynamic programming approach used 
for constructing the distance between each pair scales quadratically. 
Therefore, construction of the distance matrix for Npatients taking 
Ddrugs over a period of length Ttakes O(DN2T2) time and uses 
O(N2 +T2) memory. In cases where the exact intervals and number of 
days that the drug is administered is not crucial the time periods can be 
collapsed (e.g. from days to weeks) in order to increase computational 
and memory efficiency. 
Our strategy identifies clusters to characterize the PANS patient 
population, but cluster assignment should not be considered an associ-
ation without further investigation. This approach is merely a way to 
generate new hypotheses that could be further investigated by the 
clinical and research teams. In a polypharmacy context, this approach 
could further be used to better understand treatment patterns and 
potentially disease clusters. These patterns may represent clinician’s 
preference of treatments for certain clinical characteristics and severity 
levels, or effectiveness of a treatment such that it is continuously 
prescribed. 
We identified six apparent clusters in the PANS cohort based on their 
medication history, including initiation and cessation dates. Traversing 
the dendrogram structure in Fig. 5, one level up results in three groups of 
two sub-clusters: (a) those patients requiring high dose IV steroids 
(clusters 4 and 6); (b) patients with higher arthritic or inflammatory 
burden requiring prolonged NSAID (clusters 1 and 2), where one was 
also treated with penicillins presumably due to concerns for Strepto-
coccal infections (cluster 3); and (c) patients with mild relapsing/ 
remitting syndrome treated with a short course of NSAID (clusters 3 and 
5). 
The peak of IV corticosteroid use in Clusters 2, 4 and 6, was followed 
by a steady increase in use of several other medications (steroid sparing 
agents including DMARDS and IVIG). This pattern is consistent with a 
more severe phenotype since the clinicians in the PANS clinic reserve IV 
corticosteroids for the most severe cases, who tend to also have co-
morbid arthritis and other autoimmune diseases. This is supported by 
the outcomes data (Fig. 6, last two rows). At clinic entry, the patients in 
these clusters had a starting Global Impairment score above 40 (in a 
scale up to 100). However, the outcomes for these clusters were very 
different. Cluster 2 generally worsened throughout the two years of 
study except perhaps after the peak use of IV corticosteroids; meanwhile 
Clusters 4 and 6 generally improved overall. This differentiation on 
outcomes shows that our clustering strategy accurately captured the 
decision making process by the clinician when prescribing other drugs to 
account for the patient’s health status at the time of prescription. 
Constant heavy use of NSAIDs in Clusters 1, 2 may represent a sub-
group of patients who respond to NSAIDs but rely on the constant use of 
NSAIDS to suppress symptoms. This continued long term usage may 
reflect those patients who had recrudescence of symptoms when the 
NSAID dose was lowered. However, this group seemed to worsen over 
time which appeared to be associated with the eventual addition of more 
aggressive immunomodulation. The low Global Impairment score at 
clinic entry of Cluster 1 may have led to the decision not to use corti-
costeroids in the initial treatment. In contrast, short courses of NSAID in 
Clusters 3 and 5, were associated with improved psychometric scores 
significantly during the first half year. This pattern is compatible with 
the relapsing/remitting course of PANS illness. When the patients 
Table 2 
Clinical characteristics of 43 consecutive pre-pubertal patients with new-onset 
PANS.  
Characteristic PANS 






Age at first neuropsychiatric symptom onset (years) mean = 7.77 
SD = 2.35  
Age at first clinic visit (years)  mean = 7.93 










PANS symptoms at first presentation to the clinic 
Obsessive compulsive symptoms 
Food intake problems 
Anxiety/phobia 
Emotional lability/depression/suicidal ideation 
Aggression/irritability/opposition 
Cognitive problems 


















SD = standard deviation. *Race/ethnicity is a self-reported item on the patient 
questionnaire and more than one category could be selected. The medication list 
included seven categories of drugs: (1) penicillin, (2) cephalosporins, (3) mac-
rolides, (4) non-steroidal anti-inflammatory drugs (NSAIDs), (5) corticosteroids 
(oral and intravenous), (6) antibodies, and (7) disease-modifying anti-rheumatic 
drugs (DMARDs). For each patient, a detailed medication history was collected 
and included initiation date and intake duration. This input was then used by 
MedAl to create an edit distance matrix, from which a hierarchical cluster was 
built. 
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Fig. 4. Analysis of optimal number of clusters. (A) Elbow method, (B) Silhouette method, (C) Gap statistic method, (D) Clest method, (E) Evaluation of normalized 
mutual information (NMI), Purity and Entropy. The horizontal axis shows our variation of number of expected clusters (k), and the vertical axis shows the score 
obtained in each metric. 
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returned to near baseline, clinicians stopped most pharmacological 
treatments. 
Heavy penicillin use was observed in Clusters 2 and 5 (also moderate 
use in Cluster 3) which may indicate that the clinician had suspicion or 
evidence for a streptococcal infection, coincident with the onset of the 
psychiatric illness (an association seen in epidemiological studies [9]) 
and likely reflects the clinicians attempt to use penicillin as prophylaxis 
against streptococcus. 
The most important finding from the clinical standpoint is that there 
is a subgroup of patients who presented with relatively low GI scores and 
they slowly get better over time with minimal antibiotics and immu-
nomodulation (primarily penicillin and NSAIDS)(cluster 3 and 5). This 
appears to be a distinct group from cluster 2 (for example) where GI is 
high at clinic entry and continues to remain high and despite penicillin 
and NSAIDS (among other interventions). This data may be instructive 
in designing a clinical trial to test the effectiveness of penicillin and/or 
Fig. 5. Cluster assignment for hierarchical clustering using k = 6. (A) Heatmap of the MedAl score, clustering dendrogram in rows (hierarchical clustering, hclust) 
and columns (k-means); (B) MDS components 1 and 2 with hierarchical clustering assignment; (C) MDS components 1 and 2 with k-means assignment. 
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NSAID, but this data suggests that the initial study should probably 
select patients with relatively low GI at study entry. 
5. Limitations 
Our study was limited by a small number of patients selected for this 
study. The selection of patients was reduced from an initial cohort of 305 
patients seen in the Stanford PANS clinic to 43 pre-pubescent patients 
who met strict PANS criteria and who were new-onset at the time of 
clinic entry, such that their medication history was fully revealed in the 
charts to avoid recall bias and unclear history. Furthermore, we limited 
the timespan of medication history to only the first two years of treat-
ment, to make the patient comparisons possible. It is possible that some 
patients received additional prescriptions outside of the Stanford PANS 
clinic, and that medication would not be recorded in the EMR. Addi-
tionally, we grouped medications of similar effects into clinically 
Fig. 6. Drug usage of patients in clusters and overall impairment scales. Abbreviations: dmard: disease-modifying antirheumatic drug; nsaid: Nonsteroidal anti- 
inflammatory drug. For a full list of drug categories, please refer to Table 1. The last two rows show the Global Impairment Scale and Caregiver Burden In-
ventory, where linear model fitting for all patients in that cluster, and the color corresponds to a positive slope (red) meaning worsening of the patient; and a negative 
slope (blue), meaning an improvement on the patient’s impairment or caregiver burden. The cluster assignment was obtained from k-means. (For interpretation of 
the references to colour in this figure legend, the reader is referred to the web version of this article.) 
Table 3 
Slopes for caregiver burden inventory and global impairment scores over time by cluster.   
Global impairment score  Caregiver burden  
Intercept Slope Std. Error P-value  Intercept Slope Std. Error P-value 
Cluster 1 33.20 − 8.32 5.88 0.2234  25.78 − 3.20 4.17 0.4595 
Cluster 2 38.58 3.80 2.65 0.1562  32.60 2.17 5.05 0.6845 
Cluster 3 28.24 − 19.75 4.31 0.0002  25.05 − 20.10 5.55 0.0029 
Cluster 4 40.46 − 8.89 5.13 0.1140  39.42 − 11.90 3.13 0.0005 
Cluster 5 32.72 − 16.67 8.52 0.1060  18.69 − 5.80 3.56 0.1135 
Cluster 6 58.80 − 15.14 3.25 0.0006  37.33 − 2.70 1.94 0.1734  
ANOVA P-value = 0.0054  ANOVA P-value = 0.0004  
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relevant categories instead of treating each drug independently to in-
crease power and applicability to the clinical practice. The stricter study 
criteria and limited time frame increased comparability between pa-
tients to find patterns related to medication usage immediately after 
diagnosis and treatment initiation. In future research, selecting an 
appropriate censoring strategy and time zero should be individualized to 
research questions, as complexity of patients’ medical and drug history 
often exist in real-world data studies. 
6. Conclusion 
The field of patient similarity is expanding with the inclusion of 
novel sources of data in electronic format. In this study, we have shown 
that MedAl is capable of providing a reliable similarity metric that can 
generate new hypotheses for further investigation in a complex syn-
drome like PANS. The medication histories of other cohorts with a high 
pharmacological burden will play an important role in our under-
standing of their treatment patterns. 
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